325 related articles for article (PubMed ID: 33978983)
1. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
3. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
4. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
5. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
9. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
10. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
Kavanagh JE; Hearn AP; Dhariwal J; d'Ancona G; Douiri A; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Kent BD; Jackson DJ
Chest; 2021 Feb; 159(2):496-506. PubMed ID: 32882249
[TBL] [Abstract][Full Text] [Related]
11. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.
Bleecker ER; Wechsler ME; FitzGerald JM; Menzies-Gow A; Wu Y; Hirsch I; Goldman M; Newbold P; Zangrilli JG
Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30139780
[TBL] [Abstract][Full Text] [Related]
12. Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis.
Liu W; Ma X; Zhou W
Medicine (Baltimore); 2019 May; 98(22):e15868. PubMed ID: 31145343
[TBL] [Abstract][Full Text] [Related]
13. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
[TBL] [Abstract][Full Text] [Related]
14. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
[TBL] [Abstract][Full Text] [Related]
15. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
[TBL] [Abstract][Full Text] [Related]
16. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
[TBL] [Abstract][Full Text] [Related]
17. Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study.
Le TT; Emmanuel B; Katial R; Tran TN; Kwiatek JJ; Cohen DS; Daniel SR; Cao Y; Shih VH; Melcón MG; Devouassoux G; Pelaia G;
J Asthma Allergy; 2024; 17():313-324. PubMed ID: 38595692
[TBL] [Abstract][Full Text] [Related]
18. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
Liu T; Wang F; Wang G; Mao H
Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
